3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Leiomyosarcoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Breast Neoplasms
1
Interventions
Gemcitabine
5
Cisplatin
5
Oxaliplatin
4
pembrolizumab
3
Irinotecan
3
Carboplatin
3
Specimen Handling
2
Radiosurgery
2
Psychiatric Rehabilitation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Floxuridine
2
Erlotinib Hydrochloride
2
Cyclophosphamide
2
Cetuximab
2
Bortezomib
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
spartalizumab
1
sodium thiosulfate
1
selpercatinib
1
rucaparib
1
repotrectinib
1
pidilizumab
1
pazopanib
1
p53 peptide 264-272, human
1
motexafin lutetium
1
montanide ISA 51
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
rucaparib
×
Sarcoma
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts